The Ventricular Assist Device (VAD) has been included in the NHI benefits package since October 1, 2018. The VAD is a device for bridging to heart transplantation. Based on the follow-ups, patients with VAD in Taiwan have higher survival rates and less complications than many other countries comparing the cases in Taiwan with data in the U.S. and Europe. In addition, according to the cost-effective analysis based on the NHI database and literatures, the VAD is a cost-effective option for treatment.

Date: December 30, 2021